ALK-Abelló A/S

ALK-Abelló A/S is a Denmark-based global pharmaceutical company specializing in the development, manufacturing, and marketing of products for allergy prevention, diagnosis, and treatment. Founded in 1923 and headquartered in Hørsholm, it pioneered allergy immunotherapy, offering unique vaccination therapies in injection and tablet forms that address the root causes of allergies rather than just symptoms. The company also provides solutions for severe allergic reactions like anaphylaxis and diagnostic tools, serving over 2.4 million users across 46 countries. With approximately 2,782 employees worldwide, ALK-Abelló A/S generates significant revenue from allergy treatments, reporting 5.54 billion DKK in 2024 sales primarily from Europe, including key markets like Germany, France, and other European regions, alongside North America and international areas. Owned substantially by the Lundbeck Foundation, which holds about 34% of shares, the company drives innovation through research and strategic partnerships, particularly in Asia-Pacific, establishing itself as a leader in the pharmaceuticals sector focused on allergy care. ALK-Abelló A/S plays a vital role in global healthcare by advancing long-term allergy management solutions.